US Drug Patent 6,779,468: Claim Scope, Expiration, and Ferric Pyrophosphate Patent Landscape

US Patent 6,779,468 covers a therapeutic method rather than a ferric pyrophosphate composition. Its core claim requires parenteral administration of ferric pyrophosphate to treat iron deficiency. Dependent claims narrow the route to subcutaneous, intramuscular, transdermal, or intravenous delivery and identify an administration rate of approximately 40 mg per hour.

The patent is expired and does not create a current US blocking right. Its historical importance is that it broadly claimed parenteral ferric pyrophosphate, including intravenous use, before later products and patent families focused on ferric pyrophosphate citrate, dialysis delivery, and specific formulations.

What does US Patent 6,779,468 claim?

The independent claim has four required elements:

The activity must be a method of treating iron deficiency.
The subject must be a patient in need of that treatment.
Ferric pyrophosphate must be administered in an effective amount.
Administration must be parenteral and must provide bioavailable iron safely and effectively.

Claim 1 does not require a specific disease, formulation, concentration, device, dosage schedule, or patient population. It is therefore the broadest claim in the set.

Claim	Subject matter	Practical scope
1	Parenteral ferric pyrophosphate for iron deficiency	Broad method claim
2	Subcutaneous, intramuscular, transdermal, or intravenous delivery	Closed route limitation
3	Intravenous administration	Narrower than claim 2
4	Administration at about 40 mg per hour	Rate-limited dependent claim

The claims are method-of-treatment claims. They do not, on their face, claim:

Ferric pyrophosphate as a chemical composition;
A ferric pyrophosphate citrate complex;
A dialysis solution;
A dialysate additive;
A vial, syringe, cartridge, or infusion device;
A manufacturing process;
A specific particle size or solubility profile;
A particular iron oxidation state beyond the claimed ferric pyrophosphate;
A defined patient population such as hemodialysis patients.

How should claim 1 be construed?

Claim 1 is broad but not unlimited. A product or treatment would need to satisfy each limitation.

Ferric pyrophosphate

The claim requires ferric pyrophosphate. A product containing a different iron compound, such as iron sucrose, ferric carboxymaltose, ferric derisomaltose, sodium ferric gluconate, or ferumoxytol, would not literally satisfy this limitation.

A ferric pyrophosphate citrate product presents a more complex analysis. The presence of citrate may affect whether the administered active species is legally characterized as ferric pyrophosphate, a ferric pyrophosphate citrate complex, or a different chemical composition. Literal infringement would depend on product composition, labeling, formulation data, and claim construction. An expired patent cannot support a current infringement action, but this distinction remains relevant to historical validity and patent-family analysis.

Parenteral administration

"Parenterally administering" generally refers to administration outside the gastrointestinal tract. Claim 1 is broader than the routes expressly listed in claim 2. Intravenous, intramuscular, subcutaneous, and transdermal delivery are identified in claim 2, but claim 1 may also encompass other parenteral routes unless excluded by the specification or prosecution history.

Oral iron is outside the claim because oral delivery is not parenteral.

Treatment of iron deficiency

The method requires treatment of iron deficiency. Administration for another purpose, such as imaging, research, or iron loading without treatment of deficiency, would not satisfy this element unless the facts support the claimed therapeutic purpose.

The claim does not limit iron deficiency to absolute iron deficiency. It may encompass functional iron deficiency if the patient is being treated for inadequate available iron, subject to the patent's specification and claim-construction record.

Effective amount and bioavailable iron

"Effective amount" is a functional dosage limitation. The administered amount must be sufficient to provide the claimed therapeutic effect. The claim does not specify a fixed dose.

The phrase "so that bioavailable iron is safely and effectively administered" adds a functional result. It may be interpreted as requiring administration that produces bioavailable iron without unacceptable toxicity. It is unlikely to impose a single pharmacokinetic threshold unless the specification defines one.

What is the scope of claim 2?

Claim 2 limits the route to a closed list:

Subcutaneous;
Intramuscular;
Transdermal; or
Intravenous.

The phrase "selected from the group consisting of" generally excludes routes outside the listed group. Claim 2 is narrower than claim 1 and would not cover, for example, intraperitoneal administration unless the claim or specification supported a broader construction.

The transdermal limitation is notable because transdermal delivery is technically different from conventional injectable parenteral delivery. A patch, iontophoretic system, or other skin-based delivery system could raise separate questions about whether ferric pyrophosphate crosses the skin and whether the product delivers the claimed bioavailable iron.

What does claim 3 protect?

Claim 3 is directed specifically to intravenous administration. It requires all limitations of claims 1 and 2 plus the intravenous route.

An intravenous ferric pyrophosphate treatment would fall within the historical literal scope of claim 3 if:

The patient has iron deficiency;
Ferric pyrophosphate is administered;
The amount is effective;
The administration is intravenous; and
The treatment provides bioavailable iron safely and effectively.

Claim 3 does not require dialysis, a particular infusion time, a dialysate, or a particular formulation.

What does claim 4 mean by "about 40 mg per hour"?

Claim 4 adds a dosage-rate limitation. The word "about" prevents the claim from being restricted mechanically to exactly 40.000 mg per hour. The permissible range would depend on the specification, examples, prosecution history, and technical understanding of a skilled person.

The claim does not state whether 40 mg per hour refers to:

Total ferric pyrophosphate;
Elemental iron;
Ferric iron;
A formulation component;
A delivered rate averaged over the infusion; or
A nominal pump setting.

The ordinary reading is a rate of ferric pyrophosphate administration, but elemental-iron equivalence could become important in litigation. A product label that reports only elemental iron may not resolve the issue without formulation and molecular-weight calculations.

Claim 4 depends on claim 2, not directly on claim 3. As drafted, it therefore incorporates any route listed in claim 2, not only intravenous administration. It may cover subcutaneous, intramuscular, transdermal, or intravenous administration at approximately 40 mg per hour, unless the specification or prosecution history narrows the claim to intravenous delivery.

When did US Patent 6,779,468 lose exclusivity?

US Patent 6,779,468 is expired. It cannot currently block commercial use, manufacture, sale, or clinical administration of ferric pyrophosphate in the United States.

The patent was issued on August 24, 2004. Under the modern US patent-term framework, utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules. The patent's enforceable term ended before 2025. The expiration eliminates current infringement risk under this patent, although it does not eliminate risk under later patents covering different ferric pyrophosphate compositions, formulations, or delivery systems. (35 U.S.C. § 154)

Issue	Current assessment
Patent status	Expired
Current blocking right	None under US 6,779,468
Paragraph IV relevance	None for this expired patent
Patent-term extension relevance	No current enforceable term remains
Historical relevance	Broad foundational method claim
Freedom-to-operate impact	Must shift to later patent families

What is the Orange Book status of US Patent 6,779,468?

US Patent 6,779,468 should not be treated as a current Orange Book barrier. The Orange Book lists patents associated with approved drug products and does not revive expired patent rights. An expired patent may appear in historical records or patent databases, but it cannot support a current patent-based delay of ANDA approval.

The FDA-approved ferric products most relevant to competitive analysis include:

Product or active ingredient	Company or historical sponsor	Regulatory category
Ferric carboxymaltose	Daiichi Sankyo and associated sponsors	Small-molecule iron replacement
Iron sucrose	Vifor and generic manufacturers	Small-molecule iron replacement
Sodium ferric gluconate	Sanofi and generic manufacturers	Small-molecule iron replacement
Ferumoxytol	AMAG Pharmaceuticals, later acquired by Chiesi	Small-molecule iron replacement
Ferric derisomaltose	Pharmacosmos	Small-molecule iron replacement
Ferric pyrophosphate citrate	Rockwell Medical	Dialysis-related iron replacement

Triferic, a ferric pyrophosphate citrate product, received FDA approval for replacement of iron and maintenance of hemoglobin in adult patients with chronic kidney disease receiving hemodialysis. Triferic AVNU later provided an intravenous presentation for dialysis-related use. These products are not automatically covered by US 6,779,468 merely because they contain ferric and pyrophosphate-related chemistry. Product-specific claim language and patent status control. (FDA, 2019; FDA, 2021)

What later patents are relevant to ferric pyrophosphate?

The post-2004 landscape moved away from the broad concept of parenteral ferric pyrophosphate and toward narrower commercial implementations.

Ferric pyrophosphate citrate compositions

Later patent families associated with ferric pyrophosphate citrate generally focus on:

Soluble ferric pyrophosphate citrate complexes;
Stable aqueous formulations;
Defined ferric-to-pyrophosphate-to-citrate ratios;
Prevention of precipitation;
Parenteral or dialysate administration;
Replacement of iron during hemodialysis.

These claims can create a separate composition or formulation barrier even where the foundational method patent has expired.

Dialysate and hemodialysis delivery

Another important category covers introducing ferric pyrophosphate citrate into the dialysate stream or administering it during hemodialysis. Such claims may require:

A hemodialysis patient;
A dialysate containing an iron compound;
Continuous or repeated exposure;
A specified iron concentration;
Delivery through the extracorporeal circuit;
Maintenance of hemoglobin or iron parameters.

These limitations distinguish later dialysis patents from claim 1 of US 6,779,468, which does not require dialysis.

Intravenous formulations

Later patents may cover:

A sterile aqueous solution;
A particular pH range;
Specific stabilizers or chelating agents;
A defined iron concentration;
Container-closure systems;
Ready-to-use IV bags or vials;
Infusion schedules.

A company can therefore avoid the expired patent while still facing a live formulation or product-by-process patent.

Are there Paragraph IV challenges involving this patent?

No current Paragraph IV challenge should be attributed to US 6,779,468 because the patent is expired. Paragraph IV certifications are relevant when an ANDA applicant challenges a listed patent that remains capable of delaying approval under the Hatch-Waxman framework. An expired patent does not provide a continuing statutory basis for a 30-month stay.

Later ferric pyrophosphate citrate patents may generate Paragraph IV litigation if they are listed for an approved reference product and remain unexpired. The relevant analysis must be performed patent by patent and product by product. A Paragraph IV challenge to a later formulation patent would not invalidate or reopen US 6,779,468.

Does biosimilar risk apply?

No. Ferric pyrophosphate and ferric pyrophosphate citrate are small-molecule drug substances, not biologics for purposes of the Biologics Price Competition and Innovation Act.

Competitive entrants would generally use the ANDA pathway for a pharmaceutically equivalent small-molecule product, or a 505(b)(2) application where the product differs in formulation, route, dosage form, or clinical data requirements. Biosimilar terminology is not the appropriate regulatory framework for this patent estate.

Which companies are relevant competitors?

The competitive field divides into conventional IV iron and ferric pyrophosphate-based dialysis products.

Segment	Representative companies	Competitive issue
Ferric pyrophosphate citrate	Rockwell Medical	Dialysis-focused formulation and delivery patents
Ferric carboxymaltose	Daiichi Sankyo and commercial partners	High-dose IV iron and broad clinical use
Ferumoxytol	Chiesi	Rapid IV iron replacement
Ferric derisomaltose	Pharmacosmos	Large-dose infusion and anemia treatment
Iron sucrose	Multiple generic manufacturers	Established low-cost IV competition
Sodium ferric gluconate	Multiple generic manufacturers	Established dialysis and CKD use

The expired patent does not create a durable commercial advantage for any of these companies. Commercial differentiation instead depends on FDA labeling, administration convenience, dialysis integration, formulation stability, manufacturing scale, reimbursement, and later patent protection.

How strong is the patent estate for US 6,779,468?

The patent had broad conceptual scope but limited surviving commercial strength.

Factor	Assessment
Claim breadth	Broad at the method level
Composition protection	None apparent from the supplied claims
Route coverage	Broad in claim 1; enumerated in claim 2
Dose protection	Narrow claim 4 at approximately 40 mg/hour
Disease specificity	Limited
Device protection	None apparent
Manufacturing protection	None apparent
Current enforceability	None because expired
Design-around difficulty during term	Moderate
Current business value	Historical and freedom-to-operate context only

The patent would have been vulnerable to design-around strategies using a different iron complex, a nonparenteral route, a different therapeutic indication, or a formulation that did not meet the ferric pyrophosphate limitation. Its broadest risk was to an injectable ferric pyrophosphate product used to treat iron deficiency. Its weakest point was the absence of composition, formulation, manufacturing, and device claims.

What generic launch risks exist today?

US 6,779,468 creates no current generic launch risk because it is expired. Current launch risk depends on later patents and regulatory requirements.

Conventional IV iron

Generic entry is most advanced for iron sucrose and sodium ferric gluconate. Ferric carboxymaltose, ferumoxytol, and ferric derisomaltose require separate assessments of listed patents, exclusivity, formulation differences, and clinical development requirements.

Ferric pyrophosphate citrate

A new entrant may face:

Later composition patents;
A 505(b)(2) application rather than a straightforward ANDA;
Product-specific formulation claims;
Dialysis-delivery patents;
Clinical or pharmacokinetic bridging requirements;
Manufacturing controls for stability and precipitation;
Limited commercial scale compared with established IV iron products.

Manufacturing and IP barriers

Ferric pyrophosphate products can present technical barriers involving:

Aqueous solubility;
Precipitation control;
Iron oxidation-state stability;
Compatibility with dialysate;
Sterility and container integrity;
Consistent iron availability;
Control of pyrophosphate and citrate ratios.

These technical barriers may support later patent claims even though the basic parenteral-treatment concept is public domain.

Key Takeaways

US Patent 6,779,468 claims treatment of iron deficiency by parenteral administration of ferric pyrophosphate.
Claim 1 is the broadest claim and does not require dialysis, a particular formulation, or intravenous delivery.
Claim 2 lists subcutaneous, intramuscular, transdermal, and intravenous routes.
Claim 3 is limited to intravenous administration.
Claim 4 adds an administration rate of approximately 40 mg per hour.
The patent is expired and has no current US blocking effect.
The patent does not, based on the supplied claims, protect ferric pyrophosphate compositions, ferric pyrophosphate citrate chemistry, manufacturing processes, or delivery devices.
Current commercial risk resides in later patents covering ferric pyrophosphate citrate, dialysis delivery, IV formulations, and product-specific manufacturing methods.
Paragraph IV and biosimilar analysis is not applicable to this expired patent itself.
Ferric pyrophosphate products remain subject to separate FDA, formulation, manufacturing, and later-patent analysis.

FAQs

Is ferric pyrophosphate citrate automatically covered by US 6,779,468?

No. Coverage would depend on whether the administered product satisfies the ferric pyrophosphate limitation under the applicable claim construction. The patent is expired in any event.

Does claim 4 require intravenous administration?

Not expressly. Claim 4 depends on claim 2, which lists four routes. The specification or prosecution history could affect interpretation, but the claim text alone does not restrict the 40 mg-per-hour rate to intravenous delivery.

Can an ANDA applicant receive a Paragraph IV stay based on this patent?

No. An expired patent does not provide a current basis for a Paragraph IV litigation stay.

Does this patent cover iron sucrose or ferric carboxymaltose?

No, not on the supplied claim language. Those products contain different iron compounds and would not ordinarily satisfy the ferric pyrophosphate limitation.

Is US 6,779,468 relevant to current Triferic patent strategy?

Only historically. Triferic-related freedom to operate turns on later patents covering ferric pyrophosphate citrate compositions, dialysis delivery, formulations, and approved-product listings.

References

Food and Drug Administration. (2019). Triferic prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2021). Triferic AVNU prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2004). United States Patent No. 6,779,468. U.S. Department of Commerce.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Code. (2024). 35 U.S.C. § 271: Infringement of patent.

PCT Information
PCT Filed	December 30, 1997	PCT Application Number:	PCT/US97/23719
PCT Publication Date:	July 09, 1998	PCT Publication Number:	WO98/29434

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	311180	⤷ Start Trial
Australia	5617298	⤷ Start Trial
Australia	736053	⤷ Start Trial
Brazil	9713653	⤷ Start Trial
Canada	2276442	⤷ Start Trial
Germany	69734781	⤷ Start Trial
Denmark	0951470	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,779,468

Summary for Patent: 6,779,468